Citadel Advisors
MIST icon

Citadel Advisors’s Milestone Pharmaceuticals MIST Stock Holding History

Citadel Advisors’s Portfolio MIST Stock Details MIST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$43.2K Sell
36,300
-9,900
-21% -$17.3K ﹤0.01% 12452
2025
Q4 		$93.3K Buy
46,200
+29,200
+172% +$62.9K ﹤0.01% 11696
2025
Q3 		$34K Sell
17,000
-11,900
-41% -$20.9K ﹤0.01% 12361
2025
Q2 		$56.1K Buy
28,900
+20,700
+252% +$27.6K ﹤0.01% 11715
2025
Q1 		$6.56K Sell
8,200
-6,200
-43% -$12.3K ﹤0.01% 13746
2024
Q4 		$34K Buy
14,400
+14,200
+7,100% +$24.4K ﹤0.01% 12758
2024
Q3 		$304 Sell
200
-15,700
-99% -$22.8K ﹤0.01% 14052
2024
Q2 		$21.1K Buy
15,900
+12,600
+382% +$20.3K ﹤0.01% 12584
2024
Q1 		$5.91K Buy
3,300
+2,700
+450% +$4.38K ﹤0.01% 13714
2023
Q4 		$1K Sell
600
-800
-57% -$2.17K ﹤0.01% 13899
2023
Q3 		$4.34K Buy
1,400
+1,300
+1,300% +$4.04K ﹤0.01% 13495
2023
Q2 		$285 Sell
100
-5,600
-98% -$21.1K ﹤0.01% 14161
2023
Q1 		$22.5K Buy
+5,700
New +$20.8K ﹤0.01% 12983
2022
Q4 		– Sell
-346,600
Closed -$3.19M – 15238
2022
Q3 		$3.19M Buy
346,600
+311,400
+885% +$2.36M ﹤0.01% 4688
2022
Q2 		$209K Buy
+35,200
New +$216K ﹤0.01% 10614
2021
Q4 		– Sell
-52,100
Closed -$297K – 14387
2021
Q3 		$297K Buy
52,100
+7,300
+16% +$41.2K ﹤0.01% 11083
2021
Q2 		$246K Buy
44,800
+27,700
+162% +$157K ﹤0.01% 11729
2021
Q1 		$99K Buy
17,100
+2,800
+20% +$20.5K ﹤0.01% 12483
2020
Q4 		$96K Buy
+14,300
New +$95.7K ﹤0.01% 10247

Other funds holding MIST

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Citadel Advisors's MIST Position: Q1 2026 in Review

Citadel Advisors reduced its Milestone Pharmaceuticals (MIST) stake by 44% in Q1 2026, selling an estimated $274K and leaving 196,696 shares worth $234K. The position accounts for ﹤0.01% of the portfolio, ranked #11067.

Citadel Advisors first reported a position in MIST in Q3 2021 and has held it in 14 quarters since. The position peaked at $5.49M in Q3 2022. 86 funds tracked by Wall St. Rank hold MIST as of Q1 2026.

  • Citadel Advisors held 196,696 shares of Milestone Pharmaceuticals worth $234K as of Q1 2026.
  • Citadel Advisors sold 156,536 Milestone Pharmaceuticals shares in Q1 2026, an estimated $274K.
  • Milestone Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #11067 holding.
  • Citadel Advisors first reported a position in Milestone Pharmaceuticals in Q3 2021 and has held it in 14 quarters since.
  • Citadel Advisors's Milestone Pharmaceuticals position peaked at $5.49M in Q3 2022.
  • 86 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.